LIXT Key Statistics, Chart & Performance
The current stock price of LIXT is 4.05 USD. In the past month the price decreased by -5.81%. In the past year, price increased by 104.02%.
LIXT Latest News, Press Relases and Analysis
LIXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About LIXT
Company Profile
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in East Setauket, New York and currently employs 2 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
Company Info
LIXTE BIOTECHNOLOGY HOLDINGS
No. 2, 248 Route 25A
East Setauket NEW YORK 11733 US
CEO: John S. Kovach
Employees: 2
Phone: 13102032902
LIXTE BIOTECHNOLOGY HOLDINGS / LIXT FAQ
Can you describe the business of LIXTE BIOTECHNOLOGY HOLDINGS?
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The company is headquartered in East Setauket, New York and currently employs 2 full-time employees. The company went IPO on 2007-09-21. The firm is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The company is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
What is the current price of LIXT stock?
The current stock price of LIXT is 4.05 USD. The price decreased by -3.57% in the last trading session.
Does LIXT stock pay dividends?
LIXT does not pay a dividend.
What is the ChartMill technical and fundamental rating of LIXT stock?
LIXT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for LIXTE BIOTECHNOLOGY HOLDINGS?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) currently has 2 employees.
When does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) report earnings?
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) will report earnings on 2026-03-23.
LIXT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LIXT. When comparing the yearly performance of all stocks, LIXT is one of the better performing stocks in the market, outperforming 90.29% of all stocks.
LIXT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LIXT. No worries on liquidiy or solvency for LIXT as it has an excellent financial health rating, but there are worries on the profitability.
LIXT Financial Highlights
Over the last trailing twelve months LIXT reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 33.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.08% | ||
| ROE | -84.15% | ||
| Debt/Equity | 0 |